Biomedical interventions for HIV prevention in MSM in Amsterdam: a demonstration project

Biomedical interventions for HIV prevention in MSM in Amsterdam: a demonstration project - AMPrEP: Amsterdam PrEP program

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON42253

Enrollment

370

Registered

2015-04-23

Start date

2015-08-03

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pre-exposure prophylaxis Prevention of HIV infection with medication

Interventions

1. daily Pre-exposure prophylaxis 2.intermittent pre-exposure prophylaxis

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: see below

Exclusion criteria

Exclusion criteria: One of the following:1. Signs or symptoms of acute HIV infection2. Hepatitis B infection (i.e. HbsAg positive)3. Unlikely, in the opinion of the clinician, to comply with project schedule4. Hypersensitivity for one of the components of fixed combination tablet containing tenofovir and emtricitabine5. Creatinine clearing using cockroft gault formula:

Design outcomes

Primary

Measure	Time frame
To study acceptability, feasibility and uptake of PrEP	—

Secondary

Measure	Time frame
Secundary endpoints are: medication adherence, side effects, incidence of hiv and viral resistance in case of incident HIV infection, changes in risk behaviour and changes in STI prevalence.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)